Primecap Management Co. CA Has $229,000 Stock Holdings in Mural Oncology PLC $MURA

Primecap Management Co. CA decreased its holdings in shares of Mural Oncology PLC (NASDAQ:MURA) by 32.7% in the second quarter, Holdings Channel reports. The firm owned 92,800 shares of the company’s stock after selling 45,003 shares during the quarter. Primecap Management Co. CA’s holdings in Mural Oncology were worth $229,000 at the end of the most recent reporting period.

Separately, Emerald Mutual Fund Advisers Trust acquired a new position in shares of Mural Oncology in the 2nd quarter worth approximately $192,000. 80.21% of the stock is owned by institutional investors and hedge funds.

Mural Oncology Price Performance

MURA stock opened at $2.10 on Friday. The business has a fifty day moving average price of $2.08 and a 200 day moving average price of $2.26. Mural Oncology PLC has a fifty-two week low of $0.95 and a fifty-two week high of $4.74. The stock has a market capitalization of $36.41 million, a price-to-earnings ratio of -0.30 and a beta of 2.93.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.38. On average, equities analysts expect that Mural Oncology PLC will post -7.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MURA has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mural Oncology in a research note on Friday, October 31st. Wall Street Zen downgraded shares of Mural Oncology from a “hold” rating to a “strong sell” rating in a research note on Sunday, August 10th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $12.00.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.